FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200324473> ?p ?o ?g. }

• W4200324473 endingPage "733" @default.
• W4200324473 startingPage "725" @default.
• W4200324473 abstract "Myocardial infarction is a cardiac adverse event associated with 5-fluorouracil (5-FU). There are limited data on the incidence, risk, and prognosis of 5-FU-associated myocardial infarction.The aim of this study was to examine the risk for myocardial infarction in patients with gastrointestinal (GI) cancer treated with 5-FU compared with age- and sex-matched population control subjects without cancer (1:2 ratio).Patients with GI cancer treated with 5-FU between 2004 and 2016 were identified within the Danish National Patient Registry. Prevalent ischemic heart disease in both groups was excluded. Cumulative incidences were calculated, and multivariable regression and competing risk analyses were performed.A total of 30,870 patients were included in the final analysis, of whom 10,290 had GI cancer and were treated with 5-FU and 20,580 were population control subjects without cancer. Differences in comorbid conditions and select antianginal medications were nonsignificant (P > 0.05 for all). The 6-month cumulative incidence of myocardial infarction was significantly higher for 5-FU patients at 0.7% (95% CI: 0.5%-0.9%) versus 0.3% (95% CI: 0.3%-0.4%) in population control subjects, with a competing risk for death of 12.1% versus 0.6%. The 1-year cumulative incidence of myocardial infarction for 5-FU patients was 0.9% (95% CI: 0.7%-1.0%) versus 0.6% (95% CI: 0.5%-0.7%) among population control subjects, with a competing risk for death of 26.5% versus 1.4%. When accounting for competing risks, the corresponding subdistribution hazard ratios suggested an increased risk for myocardial infarction in 5-FU patients, compared with control subjects, at both 6 months (hazard ratio: 2.10; 95% CI: 1.50-2.95; P < 0.001) and 12 months (hazard ratio: 1.39; 95% CI: 1.05-1.84; P = 0.022).Despite a statistically significantly higher 6- and 12-month risk for myocardial infarction among 5-FU patients compared with population control subjects, the absolute risk for myocardial infarction was low, and the clinical significance of these differences appears to be limited in the context of the significant competing risk for death in this population." @default.
• W4200324473 created "2021-12-31" @default.
• W4200324473 creator A5012341363 @default.
• W4200324473 creator A5016797501 @default.
• W4200324473 creator A5025654306 @default.
• W4200324473 creator A5032789207 @default.
• W4200324473 creator A5033436516 @default.
• W4200324473 creator A5037863932 @default.
• W4200324473 creator A5038410188 @default.
• W4200324473 creator A5039314542 @default.
• W4200324473 creator A5039750321 @default.
• W4200324473 creator A5041526130 @default.
• W4200324473 creator A5043782124 @default.
• W4200324473 creator A5057514332 @default.
• W4200324473 creator A5068942402 @default.
• W4200324473 creator A5081226419 @default.
• W4200324473 creator A5087431344 @default.
• W4200324473 creator A5090671984 @default.
• W4200324473 date "2021-12-01" @default.
• W4200324473 modified "2023-10-14" @default.
• W4200324473 title "Risk for Myocardial Infarction Following 5-Fluorouracil Treatment in Patients With Gastrointestinal Cancer" @default.
• W4200324473 cites W102725257 @default.
• W4200324473 cites W1551289483 @default.
• W4200324473 cites W1779971821 @default.
• W4200324473 cites W1914185061 @default.
• W4200324473 cites W1979357362 @default.
• W4200324473 cites W1989753015 @default.
• W4200324473 cites W2019490338 @default.
• W4200324473 cites W2046603314 @default.
• W4200324473 cites W2047453652 @default.
• W4200324473 cites W2050144711 @default.
• W4200324473 cites W2072947041 @default.
• W4200324473 cites W2102420102 @default.
• W4200324473 cites W2119881391 @default.
• W4200324473 cites W2120304210 @default.
• W4200324473 cites W2120307638 @default.
• W4200324473 cites W2123291749 @default.
• W4200324473 cites W2123444915 @default.
• W4200324473 cites W2136738489 @default.
• W4200324473 cites W2153298866 @default.
• W4200324473 cites W2163352148 @default.
• W4200324473 cites W2487010569 @default.
• W4200324473 cites W2752860551 @default.
• W4200324473 cites W2808800848 @default.
• W4200324473 cites W2893785798 @default.
• W4200324473 doi "https://doi.org/10.1016/j.jaccao.2021.11.001" @default.
• W4200324473 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34988482" @default.
• W4200324473 hasPublicationYear "2021" @default.
• W4200324473 type Work @default.
• W4200324473 citedByCount "4" @default.
• W4200324473 countsByYear W42003244732023 @default.
• W4200324473 crossrefType "journal-article" @default.
• W4200324473 hasAuthorship W4200324473A5012341363 @default.
• W4200324473 hasAuthorship W4200324473A5016797501 @default.
• W4200324473 hasAuthorship W4200324473A5025654306 @default.
• W4200324473 hasAuthorship W4200324473A5032789207 @default.
• W4200324473 hasAuthorship W4200324473A5033436516 @default.
• W4200324473 hasAuthorship W4200324473A5037863932 @default.
• W4200324473 hasAuthorship W4200324473A5038410188 @default.
• W4200324473 hasAuthorship W4200324473A5039314542 @default.
• W4200324473 hasAuthorship W4200324473A5039750321 @default.
• W4200324473 hasAuthorship W4200324473A5041526130 @default.
• W4200324473 hasAuthorship W4200324473A5043782124 @default.
• W4200324473 hasAuthorship W4200324473A5057514332 @default.
• W4200324473 hasAuthorship W4200324473A5068942402 @default.
• W4200324473 hasAuthorship W4200324473A5081226419 @default.
• W4200324473 hasAuthorship W4200324473A5087431344 @default.
• W4200324473 hasAuthorship W4200324473A5090671984 @default.
• W4200324473 hasBestOaLocation W42003244731 @default.
• W4200324473 hasConcept C120665830 @default.
• W4200324473 hasConcept C121332964 @default.
• W4200324473 hasConcept C121608353 @default.
• W4200324473 hasConcept C126322002 @default.
• W4200324473 hasConcept C141071460 @default.
• W4200324473 hasConcept C164705383 @default.
• W4200324473 hasConcept C2908647359 @default.
• W4200324473 hasConcept C500558357 @default.
• W4200324473 hasConcept C526805850 @default.
• W4200324473 hasConcept C542804219 @default.
• W4200324473 hasConcept C61511704 @default.
• W4200324473 hasConcept C71924100 @default.
• W4200324473 hasConcept C72563966 @default.
• W4200324473 hasConcept C88879693 @default.
• W4200324473 hasConcept C99454951 @default.
• W4200324473 hasConceptScore W4200324473C120665830 @default.
• W4200324473 hasConceptScore W4200324473C121332964 @default.
• W4200324473 hasConceptScore W4200324473C121608353 @default.
• W4200324473 hasConceptScore W4200324473C126322002 @default.
• W4200324473 hasConceptScore W4200324473C141071460 @default.
• W4200324473 hasConceptScore W4200324473C164705383 @default.
• W4200324473 hasConceptScore W4200324473C2908647359 @default.
• W4200324473 hasConceptScore W4200324473C500558357 @default.
• W4200324473 hasConceptScore W4200324473C526805850 @default.
• W4200324473 hasConceptScore W4200324473C542804219 @default.
• W4200324473 hasConceptScore W4200324473C61511704 @default.
• W4200324473 hasConceptScore W4200324473C71924100 @default.
• W4200324473 hasConceptScore W4200324473C72563966 @default.
• W4200324473 hasConceptScore W4200324473C88879693 @default.

• next